Table 2 Difference in PASI scores and BSA at baseline and follow-up

Monoclonal antibody (mAb)

Baseline

Follow-up

Mean difference with 95% CI

p-value

Adalimumab

17.91 ± 12.65

4.19 ± 9.08

–13.71(–17.93 - − 9.49)

< 0.0001

Risankizumab

24.78 ± 20.39

1.25 ± 2.15

–23.54(–31.27 - − 15.80)

< 0.0001

BSA (%)

Monoclonal antibody (mAb)

Baseline

Follow-up

Mean difference with 95% CI

p-value

Adalimumab

23.62 ± 23.59

5.21 ± 14.38

–18.41(–26.56 - − 10.27)

< 0.0001

Risankizumab

22.71 ± 24.43

1.14 ± 1.84

–21.57(–36.38 - − 12.06)

0.0005